Novacyt admission and first day of dealings AIM ENG Paris, France and Cambridge, UK – 1st November 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce the admission of the Company’s Shares (the “Enlarged Share Capital”) to trading on AIM, a market operated by the London
Visit PageYear: 2017
PROPOSED ADMISSION TO TRADING ON AIM AND SUCCESSFUL CONDITIONAL CAPITAL RAISE OF €9.7 MILLION
Novacyt proposed admission to AIM ENG Paris, France and Cambridge, UK – 18th October 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces that it has raised a total of €9.7 million (before expenses) through a conditional placing (the “Placing”) of 7,051,590 new shares (the “Placing Shares”), raising €4.7 million, and
Visit PageNOVACYT STRENGTHENS PRIMERDESIGN BUSINESS WITH NEW SENIOR HIRE
Novacyt Senior Hire for PrimerDesign PR Eng Paul Eros joins as Commercial Director, completing investment in the Group’s senior leadership team
Visit Page